| abstract |
The present invention is concerned with pyrazolopyrimidines and pyrazolotriazines of the general formulae and their pharmaceutically acceptable salts. Surprisingly, these compounds have a selective affinity to 5HT-6 receptors. They are accordingly suitable for the treatment and prevention of central nervous disorders such as, for example, psychoses, schizophrenia, manic depressions, depressions, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea. |